Here you can find the latest resources related to CEPI:

  • Priority diseases
  • Biological Standards and Assays Working Group
  • Policies
  • Other

Priority diseases

CEPI will initially target the MERS-CoV, Lassa and Nipah viruses, which have known potential to cause serious epidemics. It aims to develop two promising vaccine candidates against each of these diseases, so these are available without delay if and when an outbreak begins.

CEPI took the WHO’s R&D Blueprint for Action to Prevent Epidemics as its starting point. This contains a list of priority pathogens against which medical countermeasures are urgently needed. CEPI’s Scientific Advisory Committee chose these three diseases based on a set of criteria including the public health impact, the risk of an outbreak occurring and the feasibility of vaccine development, based on current knowledge, tools and pipeline candidates.

More information about the priority diseases can be found here:

You can find information about the pipeline dataset for MERS, Lassa and Nipah vaccine candidates here:

CEPI is collaborating with ProMED to provide up-to-date and reliable news about the CEPI priority diseases on the frontpage of the website.

Biological Standards and Assays

Biological Standards and Assays and its Importance

Biological standardization plays a major role in advancing vaccines. International standards enable the harmonisation and standardisation of assay data which in turn allows evaluation of product development as well as on-going quality control throughout a product’s life cycle. This enables comparisons between different vaccines, on different platforms, at various stages of the product development, as well as enabling differing groups to investigate products and provide comparable data.

CEPI is working on the development of Standards and Assays through a Working Group of experts and a series of pathogen specific Task Forces to address the major needs each for Lassa, Nipah and MERS-CoV Standards and Assays. Together we can develop Standards and Assays to better compare and evaluate vaccine candidates, and to better investigate the diseases itself.

More information can be found here.


External facing policies can be found here.


Programme Document

The Preliminary Business Plan 2017-2021 sets out the mission, vision and scope of CEPI, as identified during the inception phase of the Coalition. Since the establishment of CEPI, a permanent Secretariat and governance structure has been formed and implemented. This has led to more information about the direction that CEPI is pursuing. To provide coherent and updated overview about this direction as it relates to CEPI’s strategic objectives and operations, a Programme Document has been drafted.

The Programme Document builds on the board’s investment decisions and processes, and recently approved permanent governance arrangements and CEPI policies. The Programme Document also provides new information around CEPI’s theory of change and how it relates to achievement of goals and milestones depicted in the results framework. Moreover, a detailed risk assessment and description of the selection and decision process of the Calls for Proposals (CFP) is included.

As CEPI has continuously been evolving throughout its start-up phase, the Secretariat is committed to presenting a revised Business Plan by the end of third quarter of 2018. Together with the Preliminary Business Plan, this Programme Document will serve as a point of departure when developing and drafting CEPI’s revised Business Plan. If there are important decisions that CEPI wants to have reflected in documentation in advance of the finalisation of the Business Plan, the Secretariat may amend the Programme Document in the months to come.

The Programme Document can be found here.

Vaccines against Emerging Infections - a Global Insurance

The first CEPI Scientific Community Meeting took place in Paris on 21 and 22 February.

CEPI Ebola vaccines regulatory scientific meeting

On March 22nd 2017 CEPI organized a regulatroy scientific meeting, hosted by the National Academy of Science to address the regulatory science gaps on the Ebola vaccines.

This meeting enabled us to look into future regulatory scientific research areas which will be further refined and taken forward in smaller task forces. The Secretariat has been closely working with the organizing committee to finalize a short meeting report which can be found here.



Summary review on vaccine regulatory pathways important for CEPI

This summary review on vaccine regulatory pathways important for CEPI was initiated under Task Team 1, specifically the sub-groups looking at clinical development and regulatory affairs groups. The purpose of this summary is to provide an overview of the current regulatory standards available for EIDs in an emergency. This summary will be a reference for future work related to vaccine and regulatory pathways important for CEPI and an important tool to further engage and work with regulatory partners on collaborative efforts to provide advice and negotiate on regulatory and ethical pathways for vaccines for and during epidemics. A working group focused on regulatory affairs will develop a work plan and coordinate further work with the CEPI Scientific Advisory Committee (SAC) and Joint Coordination Group (JCG). 



Appendix to the summary review